Clinical Trial Update: A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL) [Phase 2]

View source ↗

Summary

Phase 2 trial comparing subcutaneous versus intravenous rituximab in combination with CHOP for previously untreated CD20-positive diffuse large B-cell lymphoma;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Lymphoma, Large B-Cell, Diffuse | Phase 2 | Status: COMPLETED | Results posted: 2023-07-27